Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

During the Trading Day
538.00 +2.53 / +0.47%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
538.00 0.00 / 0.00%
 
Volume: 12.5K
Oncolytics' Reolysin Phase II Lung Cancer Study Enrolled
4:15pm / Zacks.com
Raptor (RPTP) to Buy Quinsair, Boost Rare Disease Portfolio
Aug 21 / Zacks.com
Regeneron Pharmaceuticals (REGN) Stock Is the 'Chart of the Day'
12:02pm / TheStreet.com
Vascular (VBLT) Starts Patient Dosing in Glioblastoma Study
Aug 21 / Zacks.com
Regeneron Shows a High Volume Bottom
10:02am / TheStreet.com
Why Eli Lilly (LLY) was a Bright Spot in the Market on Thursday
Aug 21 / Zacks.com
How China's Troubles Affect Biotech and Pharma Stocks: Part 1
6:15am / TheStreet.com
Google's 11-Year Dream Run: From IPO to Alphabet
Aug 20 / Zacks.com
J&J to Sell Sugar Substitute Splenda to Heartland Food
Aug 26 / Zacks.com
This Is a Concern That Amgen Investors Shouldn't Take Lightly
Aug 20 / MotleyFool.com
Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review
Aug 26 / Zacks.com
Kite Pharma Provides Update, Death Not Related to KTE-C19
Aug 18 / Zacks.com
Drugs Stocks On The Rise With Help From 3 Stocks
Aug 26 / TheStreet.com
BioLineRx Up on Phase IIb Study Initiation on Leukemia Drug
Aug 18 / Zacks.com
Bouncing Biotech? 3 Stocks To Buy
Aug 25 / MotleyFool.com
Are the 3 Best-Performing Big-Cap Biotech Stocks of 2015 Still Worth Buying?
Aug 17 / MotleyFool.com
Seres (MCRB) Up on Orphan Drug Status for Lead Candidate
Aug 24 / Zacks.com
CVS Health Draws a Line in the Sand
Aug 15 / MotleyFool.com
Alkermes' (ALKS) Aristada Review Date Postponed by FDA
Aug 24 / Zacks.com
Emergent BioSolutions Gets $44M CDC Contract for VIGIV
Aug 14 / Zacks.com
Bull Or Bear? Biotech's Post-Earnings Buys and Sells
Aug 23 / MotleyFool.com
Avalanche Biotechnologies (AAVL) Q2 Loss Narrows Y/Y
Aug 14 / Zacks.com
Pfizer's (PFE) Breast Cancer Drug Ibrance Under EU Review
Aug 21 / Zacks.com